SCHEMBL175198

SCHEMBL175198

C1CCNCC[N]C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL566326 0.97 ALDH1A1 (0.53)
SCHEMBL675729 0.94 ALDH1A1 (0.50)
SCHEMBL7509079 0.92 ALDH1A1 (0.47)
SCHEMBL674177 0.90 ALDH1A1 (0.60)
SCHEMBL10036 0.90
SCHEMBL1782168 0.90 CXCR4 (0.41)
SCHEMBL567977 0.88 ALDH1A1 (0.56)
SCHEMBL674050 0.85 CXCR4 (0.53)
SCHEMBL235202 0.83
SCHEMBL1782490 0.83 HIF1A (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814698-B2 Methods for simultaneous leaching and extraction of precious metals EXCIR WORKS CORP. (CA) 2023-11-14 US claimed
US-20220340998-A1 METHODS FOR SIMULTANEOUS LEACHING AND EXTRACTION OF PRECIOUS METALS EXCIR WORKS CORP. (CA) 2022-10-27 US claimed
US-11427886-B2 Methods for simultaneous leaching and extraction of precious metals EXCIR WORKS CORP. (CA) 2022-08-30 US claimed
US-10087167-B2 Benzofurans substituted with secondary benzamide as HCV inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-10-02 US claimed
US-20180142322-A1 METHODS FOR SIMULTANEOUS LEACHING AND EXTRACTION OF PRECIOUS METALS UNIVERSITY OF SASKATCHEWAN (CA) 2018-05-24 US claimed
US-20180112289-A1 METHODS FOR SELECTIVE LEACHING AND EXTRACTION OF PRECIOUS METALS IN ORGANIC SOLVENTS UNIVERSITY OF SASKATCHEWAN (CA) 2018-04-26 US claimed
US-20180099953-A1 BENZOFURANS SUBSTITUTED WITH SECONDARY BENZAMIDE AS HCV INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-04-12 US claimed
US-9707202-B2 Certain chemical entities, compositions, and methods NEUPHARMA, INC. (US) 2017-07-18 US claimed
US-20160303066-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2016-10-20 US claimed
WO-2016133963-A1 BENZOFURANS SUBSTITUTED WITH SECONDARY BENZAMIDE AS HCV INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-08-25 WO claimed
EP-1218372-B1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMA (US) 2003-07-02 EP claimed
US-20030119827-A1 Novel nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-06-26 US claimed
EP-0806419-B1 Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator MEIJI SEIKA KAISHA (JP) 2003-04-02 EP claimed
US-20030013730-A1 Serotonin 5-HT3 receptor partial activator MEIJI SEIKA KAISHA, LTD. 2003-01-16 US claimed
WO-2002100849-A2 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2002-12-19 WO claimed
EP-1218372-A1 NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES Boehringer Ingelheim Pharmaceuticals, Inc. (US) 2002-07-03 EP claimed
US-20020058809-A1 Compounds useful as reversible inhibitors of cysteine proteases EMMANUEL MICHEL JOSE (US) 2002-05-16 US claimed
US-20010016579-A1 Serotonin 5-HT, receptor partial activator LOTUS PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 US claimed
WO-2001019816-A1 NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2001-03-22 WO claimed
EP-0806419-A1 Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator MEIJI SEIKA KAISHA LTD. (JP) 1997-11-12 EP claimed